FDA
-
-
-
-
-
-
-
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
-
-
-
-
-
-
-
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
-
-
-
-
-
-
-
Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'
-
-
-
-
-
-
-
4DMT (FDMT) Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
-
-
-
-
-
-
-
Chardan Capital Markets Starts 4D Molecular Therapeutics (FDMT) at Buy
-
-
-
-
-
-
-
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Aevitas Therapeutics, a Fortress Biotech (FBIO) Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

